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Tumour hypoxia – a common phenomenon in clinical oncology –
is an important factor known to be able to modulate the sensitivity
of tumours to several non-surgical tumour treatment modalities,
such as standard radiotherapy, chemotherapy with O2-sensitive
agents or photodynamic therapy (Bush et al, 1978; Freitas and
Baronzio, 1991; Hall, 1994; Horsman, 1993). In addition, the
oxygenation status seems to affect biological properties of
tumours which appear to be relevant in terms of their malignant
behaviour (e.g. metastatic or apoptotic potential) (Giaccia, 1996;
Graeber et al, 1996). For this reason, tumour oxygenation is an
independent parameter predicting for the long-term prognosis
(local control, overall survival) of cancer patients (Brizel et al,
1996; Höckel et al, 1993; 1996; Nordsmark et al, 1996).
The oxygen deficiency found in tumours results presumably
from an imbalance of oxygen supply to the tissue and the oxygen
consumption of the cells (Vaupel, 1993; Gulledge and Dewhirst,
1996). One major reason for the insufficient O2 transport to the
tissue is the inadequate and chaotic microvascular network
showing a series of morphological and functional abnormalities.
In tumour microvessels, for instance, tortuosity, excessive
branching, blind endings, lack of contractile elements (smooth
muscle cells), as well as interrupted endothelial linings and base-
ment membranes, can be found (Konerding et al, 1995). These
vascular networks have no hierarchical organization (Konerding
et al, 1995) and show significant arterio-venous shunt perfusion as
well as temporal variations in red cell flux (short of vascular stasis)
(Kimura et al, 1996) or even intermittent blood flow with tempo-
rary stasis (Chaplin and Hill, 1995). These functional abnormali-
ties lead to an insufficient nutrient and oxygen supply of the
tumour tissue (Braun et al, 1999; Dewhirst et al, 1998; Vaupel
et al, 1989).
The inadequate blood flow through the tumour is relevant not
only for the oxygenation status but also for the pharmacokinetics
of anticancer agents. Studies analysing the spatial distribution of
perfusion within a tumour showed pronounced heterogeneity
which might compromise drug delivery to some regions of the
tumour (Tozer et al, 1996).
For these reasons, many attempts have been undertaken with the
aim of increasing tumour perfusion and oxygen supply to the cells
to improve treatment efficacy of radio- and/or chemotherapy.
Several possible mechanisms have been analysed for their capa-
bility of modulating tumour perfusion (Jain and Ward-Hartley,
1984; Vaupel et al, 1998; 2000): (i) vasoactive agents, (ii) rheolo-
gically active drugs, (iii) haemodilution, (iv) lowering interstitial
hypertension, (v) mild (low-dose) hyperthermia, and (vi) agents
reducing intermittent occlusion of tumour vessels (Jirtle, 1988;
Kelleher et al, 1998; Powell et al, 1997).
When vasoactive drugs are considered, these can be used in two
different ways to enhance tumour blood flow. Firstly, vasodilators
might be suitable to bring about a dilation of tumour feeding
vessels and, by reducing the vascular (geometric) resistance of the
tumour, might lead to an increase in perfusion (as long as an
adequate perfusion pressure can be maintained). Secondly, vaso-
constrictive agents supplied systemically might, by causing an
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flow in favour of the tumour.
However, the efficacy of vasoactive drugs seems to be question-
able due to the functional abnormalities of tumour microvessels.
Vasodilators (e.g. NO-donating drugs) may only be effective on
tumour vessels which are previously in a contracted state.
However, many tumours lack vascular smooth muscle cells
(Konerding et al, 1989b; 1989c). In addition, the low extracellular
pH (Vaupel et al, 1989) and elevated levels of NO (Dworkin et al,
1995, Kennovin et al, 1994) found in tumours both lead to a
maximal vasodilation. For these reasons the use of vasodilators
(especially NO-donors) to improve tumour perfusion and/or
oxygenation may not be appropriate (Shan et al, 1997). At the
other extreme, increasing the perfusion pressure by a systemic
vasoconstriction might only be effective if tumour vessels were
not to react to the vasoconstrictive stimulus. It has been postulated
that in many solid tumours the vascular system behaves like a
chaotic network of rigid tubes. An increase in mean arterial blood
pressure (MABP) should therefore result directly in an improve-
ment of blood flow through the tissue and subsequently in a
change of the O2 and substrate supply to the tumour cells. Another
aspect of using vasoconstrictive drugs for increasing blood pres-
sure might be an improvement of the convective transport of
macromolecules to the tumour cells. By increasing the blood pres-
sure the extravasation of these molecules out of the vasculature
into the interstitial space can be enhanced (e.g. Netti et al, 1999).
An alternative measure to improve tumour perfusion is the appli-
cation of rheologically active agents, which can reduce viscous
resistance of the blood flowing through the tumour (Kelleher et al,
1998).
The aim of this study was to analyse the impact of the vasocon-
strictive drug angiotensin II on perfusion and oxygenation of
experimental tumours. In particular, the investigation assesses
whether changes in perfusion pressure result in comparable
changes in tumour blood flow (as would be expected for a system
of rigid tubes), or whether vasoactive effects take place in the
tumour vascular system.
MATERIALS AND METHODS
Animals and tumours
Studies were performed using DS-sarcomas implanted subcuta-
neously onto the hind foot dorsum of male Sprague-Dawley rats
(body weight 180–250 g). Animals were allowed access to a stan-
dard diet (type 1324; Altromin, Lage, Germany) and water ad
libitum prior to experiments. For tumour implantation 0.4 ml of
DS-sarcoma ascites (approximately 104 cells ml–1) was injected.
Within 6–12 days tumours grew as flat, spherical segments and
replaced the subcutis and corium completely with volumes of
0.5–2.5 ml. Up to this volume the tumour grows without being
limited by the restricted space of the subcutaneous tissue on the
hind foot dorsum (as confirmed by the exponential growth
observed) and without inducing pain or an elevated tissue pressure
due to a non-compliant capsula. Volumes were determined by
measuring the three orthogonal diameters of the tumour and using
an ellipsoid approximation with the formula: V = p/6 ´ d1 ´ d2 ´ d3.
From the volume-growth curves, the volume doubling time was
calculated during exponential tumour growth. All experiments had
previously been approved by the regional animal ethics committee
and were conducted in accordance to the German Law for Animal
Protection and the UKCCCR Guidelines (UKCCCR, 1998).
Surgical procedures
When tumours reached the desired volume, rats were anaesthetized
with sodium pentobarbital (40 mg kg–1 i.p., Nembutal; Ceva, Paris,
France). Throughout all experiments, animals lay supine on a
heated operating pad with the rectal temperature main-
tained at 37.5–38.5°C. Animals breathed room air spontaneously.
Mean arterial blood pressure (MABP) was continuously monitored
through connection of an arterial catheter placed in the left carotic
artery to a Statham pressure transducer (type P23 ID; Gould,
Oxnard, CA, USA). A second catheter placed in the external jugular
vein was used to continuously infuse angiotensin II.
Angiotensin II infusion
Angiotensin II (AT II; Sigma, Deisenhofen, Germany) was
dissolved in isotonic saline at a concentration of 6 mg ml–1. This
solution was continuously infused over 30 min with the infusion
rate being adjusted (0.5–2.0 mg min–1 kg–1 body weight) to achieve
an increase in MABP of 50–70 mmHg. Due to fast adaptation of
the animals to AT II, the infusion rate had to be increased during
the experiments in order to maintain the target increase in blood
pressure.
Oxygenation measurement
The spatial distribution of tumour oxygen tensions (pO2) was
measured polarographically using steel-shafted microelectrodes
(outer diameter 300 mm) and pO2 histography (Eppendorf,
Hamburg, Germany; for more details of this method see Vaupel
et al, 1991). A small midline incision was made in the skin
covering the lower abdomen and the Ag/AgCl reference electrode
placed between the skin and the underlying musculature. For
tumour  pO2 measurement, a small incision was made into the skin
overlying the tumour using a 24-gauge needle and the electrode
advanced to a depth of approximately 1 mm. The electrode was
then automatically moved through the tissue in pre-set steps with
an effective step length of 0.7 mm (Vaupel et al, 1991).
Approximately 100 pO2 values were obtained from each tumour in
up to 12 parallel electrode tracks with a horizontal distance of
1–3 mm. The oxygenation status of each tumour was described by
the mean and median pO2, as well as the fraction of pO2 values
≤2.5 mmHg and ≤5 mmHg. Oxygenation studies of individual
tumours were generally carried out in less than 20 min.
Additionally, arterial blood gas analysis was performed immedi-
ately before and after tumour tissue pO2 measurements, using a
pH/blood gas analyser (Type 178; Ciba Corning, Fernwald,
Germany) to ensure that animals had arterial blood gases within
the physiological range during the measurement period.
For assessing temporal changes in tissue oxygenation, mean
tumour pO2 was measured continuously using polarographic
catheter electrodes of the Clark type (Licox; GMS, Kiel,
Germany). The O2-sensitive cathode has a length of 5 mm and is
placed in a O2-permeable flexible catheter with an outer diameter
of approximately 350 mm. For positioning of the electrode a
catheter was inserted into the tumour along its long axis. After
placing the electrode in the trocar, the catheter was withdrawn
leaving the electrode in the tumour centre. Measured pO2 values
were averaged over a period of 1 min. Continuously measured pO2
data were expressed relative to the pO2 value immediately prior to
the start of AT II infusion.
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Red blood cell (RBC) flux was measured using the laser Doppler
technique (semiconductor laser diode, wavelength 780 nm, output
power 1–2.5 mW, cut-off frequency 15 kHz, Oxford Array;
Oxford Optronics, Oxford, UK). Details of this method have been
described earlier by Kelleher et al (1995; 1998). In each tumour
RBC fluxes were obtained from three different central and periph-
eral locations in the tissue using needle probes (Model MPM NP,
o.d. 0.5 mm). For insertion of the probe a small incision was made
with a 24-gauge needle in the skin covering the tumour, such that
bleeding from the wound was kept to a minimum. Total
backscatter was recorded continuously in order to optimize probe
positioning and to ensure a constant probe location. In cases where
flux artefacts due to alteration of probe position (e.g. as a result of
movement) occurred (as indicated by a sudden change in total
backscattered light), the flux values obtained from these channels
were excluded from further analysis. At the end of each experi-
ment, the probes were left in place and the animal was sacrificed
by an overdose of anaesthetic to obtain the ‘biological zero’ laser
Doppler signal (which was always < 15% of the RBC flux at
t = 0 min). After subtracting the ‘biological zero’ value, data were
expressed as relative RBC flux, and represent percentage values
related to the flux measurement immediately prior to the AT II
infusion. RBC flux measurements were performed 30 min before,
during and for 30 min after AT II infusion.
As a measure of the resistance to flow, the relative tumour
vascular resistance (TVR) was calculated from the ratio of the
normalized mean arterial blood pressure and the RBC flux.
Statistical analysis
Results are expressed as means ± standard error of the mean
(SEM). Differences between various groups were assessed by the
two-tailed Wilcoxon-test for unpaired samples. The significance
level was set at a = 5%. For regression analysis, continuously
measured signals were averaged for each 2 min interval and the
correlation of two signals was calculated by the correlation
coefficient (r).
RESULTS
Angiotensin II (AT II) infusion led to a significant increase in the
mean arterial blood pressure (MABP) of up to 200 mmHg. The
effect was dose-dependent and disappeared within a few minutes
when the infusion was stopped.
The change in MABP as a result of AT II infusion was accom-
panied by changes in RBC flux, the pattern of these changes being
tumour volume-dependent. Figure 1 shows two examples of
MABP and relative RBC flux in a small (volume = 0.57 ml, Figure
1A) and a large tumour (volume = 2.05 ml; Figure 1B) during
intermittent infusion of AT II. In the small tumour, the AT II-
induced increase in blood pressure was accompanied by a signifi-
cant worsening of tumour perfusion as indicated by a decrease in
RBC flux down to 50% of the pretreatment level (Figure 1A). This
effect on tumour blood flow was completely reversible. In the case
of the large tumour, increasing MABP led to a rise in tumour
perfusion parallel to changes in blood pressure (Figure 1B).
In order to quantify the impact of various tumour volumes on
the response of tumour perfusion to AT II, MABP and RBC flux
values were averaged and correlated for every 2-min interval
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Figure 1 Courses of MABP and RBC flux during intermittent application
of angiotensin II in tumours of different sizes. (A) small tumour, volume =
0.57 ml. (B) large tumour, volume = 2.05 ml. Grey bars indicate periods of
AT II infusion (demonstration of characteristic experiments).
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Figure 2 Examples of the relationship between mean arterial blood
pressure and (A) RBC flux, and (B) resistance to flow (TVR) during
angiotensin II infusion in a small (volume = 0.75 ml) and a large (volume =
1.82 ml) tumour. Each point represents the mean value of a 2-min interval.during AT II infusion. Figure 2 shows examples of the correlation
between MABP and RBC flux and resistance to flow (TVR =
MABP/RBC flux), for a small (volume = 0.75 ml) and a large
(volume = 1.82 ml) tumour, respectively. Although the perfusion
pressure increases during AT II application, the perfusion in the
small tumour decreases (r = –0.60) whereas the TVR significantly
increases (r = 0.94, Figure 2B). The large tumour shows a different
behaviour. During AT II infusion, RBC flux increases with rising
MABP (r = 0.57, Figure 2A) and the resistance to flow (TVR)
is almost unaffected by the AT II-induced increase in MABP
(r = 0.11, Figure 2B) indicating that the elevated tumour perfusion
during AT II application is most probably the result of an increased
perfusion pressure. On average, this behaviour of tumours of
different sizes has been found in almost all tumours investigated.
Figure 3 shows the correlation coefficients for each tumour
separated for the different tumour volume groups.
Since perfusion is a paramount parameter determining the
oxygenation status of tumours, the volume-dependent differences
in tumour blood flow upon AT II application should be reflected in
the pO2 distribution in the tissue. In order to quantify the impact of
AT II-induced changes on mean pO2 in tumours of different
volumes,  pO2 and MABP values were continuously monitored and
averaged for every 2-min interval from 14 min before until 14 min
after the end of AT II infusion. These averaged values of both
parameters were then correlated. The initial pO2 showed
pronounced tumour volume-dependent differences (mean pO2 =
31 ± 6 mmHg in small tumours with a volume < 1.0 ml, 30 ± 6
mmHg in medium-sized tumours with a volume of 1.0–< 1.5 ml
and 9 ± 4 mmHg in large tumours with a volume ³ 1.5 ml). For
this reason, the measured pO2 was normalized for each tumour to
values prior to commencement of AT II infusion. Figure 4 shows
two examples of the correlation between MABP and normalized
tumour pO2 for a small (volume = 0.66 ml) and a large (volume =
2.34 ml) tumour. In the small tumour, the mean pO2 decreased
with increasing MABP during angiotensin infusion (r = –0.81)
indicating an AT II-induced worsening of tumour oxygenation,
presumably due to the observed decrease in RBC flux. In the
larger tumour, the mean tumour pO2 improved significantly
parallel to the AT II-induced increase in MABP (r = 0.79). Figure
5 shows the coefficients of all tumours investigated for the correla-
tion between MABP and mean tumour pO2. On average it could be
demonstrated that in small tumours oxygenation worsens with
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Figure 3 Correlation coefficients of each tumour for the relationship
between MABP and RBC flux and TVR, respectively, in different volume
groups. The horizontal lines represent the median of the coefficients in each
group (n = numbers of tumours investigated).
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Figure 4 Examples of the relationship between MABP and mean tumour
pO2 (normalized to pretreatment pO2) before, during and after angiotensin II
infusion in a small (volume = 0.66 ml) and a large (volume = 2.34 ml) tumour.
Each point represents the mean value of a 2-min interval.
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Figure 6 Volume dependency of tumour oxygenation (expressed by the
median pO2 and the fraction of pO2 measurements ≤2.5 mmHg) in control
tumours (open triangles) and during continuous AT II infusion (dots). Each
point represents a minimum of six tumours.increasing MABP (as indicated by a negative correlation coeffi-
cient) whereas in large tumours pO2 increases with increasing
MABP (positive correlation coefficient).
This tumour-volume-dependency of the angiotensin effect on
tumour oxygenation is also reflected in the spatial pO2 distribution.
During AT II infusion the oxygenation of small tumours (volume
< 1.1 ml) is worsened (expressed by a decrease in median pO2
from 14 to 3 mmHg and an increase in the fraction of hypoxic pO2
values ≤ 2.5 mmHg from 32 to 48%, Figure 6), whereas in larger
tumours (volume ³ 1.1 ml), the O2 status was significantly
improved. The spatial analysis of the pO2 distribution showed that
the improvement in large tumours is most pronounced in the
tumour periphery, whereas more central regions remained almost
completely hypoxic (as was the case in untreated control tumours).
DISCUSSION
Newly formed tumour vessels show several structural and func-
tional abnormalities (e.g. loss of vascular hierarchy, arterio-venous
shunting) (Konerding et al, 1989a–c). In particular, the absence of
a functioning innervation, smooth muscle cells and/or physiolog-
ical receptors in these vessels results in an incapability to regulate
perfusion to meet the tissue’s demands (Mattsson et al, 1979;
Peterson, 1983; 1991; Reinhold, 1979; Warren, 1979). At the same
time however, normal vessels of the host tissue are incorporated
into the growing tumour mass (Day, 1964; Mattsson et al, 1979;
Warren, 1979). Thus, the rate and distribution of blood flow within
a tumour reflects: (i) the fraction of newly formed tumour vessels
as opposed to incorporated host vasculature; (ii) the arrangement
of these different vessel populations within the tumour (parallel vs
serial); and (iii) the structural organization of tumour vasculature
relative to the surrounding (non-incorporated) normal tissue
vessels, which may result in steal or anti-steal effects (Hirst, 1989;
Vaupel, 1993). Vasoactive drugs affecting the functionally intact
formerly host-tissue vessels can thus alter tumour perfusion in
various ways. Where tumour vessels show no vasomotive respon-
siveness and are located parallel to the host-tissue vessels, a rise in
MABP should increase tumour blood flow since in this case
tumour vessels might react as a network of rigid tubes that will be
better perfused due to the higher perfusion pressure.
For this reason, previous experiments have analysed the effects
of (systemic) vasoconstriction on tumour perfusion and oxygena-
tion. In early investigations adrenaline was used for inducing vaso-
constriction. In these studies a reduction of tumour perfusion was
usually observed (Cater et al, 1962; Gullino and Grantham, 1961;
Mattsson et al, 1980). The use of AT II as a strong vasoconstrictor
led to non-uniform results. In some studies AT II resulted in a
passive expansion of the vascular bed due to the increased perfu-
sion pressure (Hori et al, 1985; 1993), an increase in tumour perfu-
sion (Shankar et al, 1999; Suzuki et al, 1981; 1984; Tokuda et al,
1990; Trotter et al, 1991), as well as a reduction in the fraction of
transiently occluded microvessels (Hemingway et al, 1992; Trotter
et al, 1991). In contrast, other studies showed a decrease in tumour
perfusion during systemic application of AT II (Dworkin et al,
1997; Jirtle et al, 1978; Tozer and Shaffi, 1993; 1995; Tozer et al,
1996). Hirst et al (1991) demonstrated that the effect of AT II
depended on the site of tumour implantation. In subcutaneously
implanted tumours perfusion improved, whereas intra-abdomi-
nally growing tumours showed a decrease in blood flow. In
the same way as perfusion, tumour oxygenation was also
non-uniformly affected by AT II infusion (Suzuki et al, 1982).
In the present study, the impact of angiotensin on perfusion and
oxygenation was tumour volume dependent. In small tumours
(volume < 1.0 ml), both parameters worsened showing a negative
correlation between the AT II-induced increase in MABP and RBC
flux or tumour pO2, respectively (Figures 2–5). In larger tumours
(volume ³ 1.5 ml), an improvement of perfusion and O2 status
with increasing MABP by AT II was seen (Figures 2–5). These
tumour volume-dependent differences (in the same tumour model
under identical experimental conditions) might be explained by the
different responsiveness of tumour vessels upon AT II application
in small and large tumours. Presumably, the AT II-induced
increase in resistance to flow in small tumours (Figures 2B and 3)
and the reduction in tumour perfusion is the result of a substantial
vasoconstriction of the incorporated host vessels, i.e. the fraction
of these functionally intact vessels is therefore responsible for the
described net effect. In contrast, in large tumours, the perfusion
seems to passively follow changes in systemic blood pressure
according to Hagen–Poiseuille’s law. This may reflect the overall
inability of the vascular network to respond to AT II as seen by the
lack of significant changes in TVR (Figures 2B and 3). Three
reasons for the lack of reactivity of the tumour neovasculature to
AT II have to be discussed: (i) many newly formed tumour vessels
show no smooth muscle cells (Konerding et al, 1995; Warren,
1979), (ii) the density of AT II receptors is significantly reduced in
these vessels compared with normal tissue vasculature (Andrade et
al, 1998; Kohzuki et al, 1998; Tozer et al, 1996), and (iii) elevated
levels of nitric oxide (NO) in these tumours (Kennovin et al,
1994). The third phenomenon might play a role since the DS-
sarcoma shows a tumour-volume dependency of oxygenation
leading to more pronounced hypoxia in larger tumours (Figure 6)
which can in turn result in elevated levels of NO as compared to
smaller tumours. NO has been shown to diminish pharmacologi-
cally induced vasoconstriction (Dworkin et al, 1995), which might
explain the lack of responsiveness in larger tumours.
Differences in the density of AT II receptors might also be
important for the spatial heterogeneity of the AT II-induced effect
on tumour perfusion. Tozer et al (1996) described a significant
decrease of tumour blood flow in peripheral areas of experimental
P22 carcinosarcomas following AT II infusion, whereas perfusion
in the tumour centre was almost unaffected. This pattern of spatial
perfusion distribution upon AT II correlated well with the distribu-
tion of AT II receptor expression in tumour vessels found to be
approximately 10% higher in the periphery (Tozer et al, 1996).
The higher sensitivity of the tumour periphery to AT II might
therefore be the reason for the observed vasoconstriction in these
tumour areas. The authors also demonstrated that the change in
tumour perfusion upon AT II, as well as the distribution of AT II
receptors, show pronounced heterogeneity so that the overall (net)
effect of AT II on tumour blood flow cannot be predicted.
As Hirst et al (1991) demonstrated, the site of tumour growth
plays an important role in the responsiveness of tumour vessels to
AT II. The DS-sarcoma used in the present study also shows differ-
ences in the vascular pattern when implanted into different host
tissues (Vaupel and Gabbert, 1986) which in turn influences the
nutrient supply and tumour oxygenation (Vaupel and Gabbert,
1986; Vaupel and Mueller-Klieser, 1986). However, if DS-
sarcomas were implanted into the same host tissue (subcutis) but at
different locations (e.g. hind foot dorsum, thigh), these parameters
showed comparable values. For this reason, the results from the
site of tumour growth used in the present study should be compa-
rable to other s.c. locations used in experimental studies. Although
Disparate responses of tumour vessels to AT II 229
British Journal of Cancer (2000) 83(2), 225–231 © 2000 Cancer Research Campaigndifferences in the vascular pattern of the tumour depending on the
host tissue have been demonstrated, the present study clearly
shows that under well-defined experimental conditions (same
tumour model, same site of implantation) the responsiveness of the
tumour vasculature to AT II strongly depends on the tumour
volume.
Since in larger tumours perfusion increases with rising blood
pressure, it can be concluded that in DS-sarcomas newly formed
tumour vessels and pre-existing host-tissue vessels are arranged
mostly parallel to each other. In small tumours however, function-
ally intact vessels appear to be located proximately to the tumour
vessel network, because in these tumours AT II-induced vasocon-
striction led to a worsening in tumour perfusion. Obviously, the
fraction of functionally insufficient vessels from neovasculariza-
tion increases during tumour growth whereas the (relative) number
of integrated normal host-tissue vessels is reduced. From the
results of the present study, it can be concluded that improving
perfusion and oxygenation by systemic vasoconstriction is only
possible in some tumours. Since the behaviour of tumour vessels
to vasoconstrictive agents cannot be predicted a priori (Tozer et al,
1996), the applicability of these drugs in the clinical setting is
questionable.
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